WO2003087163A1 - Procede d'elaboration d'une banque scdb - Google Patents
Procede d'elaboration d'une banque scdb Download PDFInfo
- Publication number
- WO2003087163A1 WO2003087163A1 PCT/JP2003/004773 JP0304773W WO03087163A1 WO 2003087163 A1 WO2003087163 A1 WO 2003087163A1 JP 0304773 W JP0304773 W JP 0304773W WO 03087163 A1 WO03087163 A1 WO 03087163A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- variable region
- antibody
- antigen
- chain variable
- gene
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
Definitions
- the present invention relates to a single chain diabody (scDb) library and a method for producing the same.
- the present invention relates to a gene constituting the single-chain diapody library, an expression vector containing the gene, and a method for producing them, and further relates to a peptide encoded by the gene.
- Multispecific antibodies eg, bispecific antibodies (BsAb)
- BsAb bispecific antibodies
- Multispecific antibodies can be used, for example, when immobilizing enzymes used in enzyme immunoassays.
- one arm of the multispecific antibody is designed to bind to a portion of the enzyme that does not inhibit the enzymatic reaction on the enzyme, and the other arm is designed to bind to the carrier to be immobilized.
- the enzyme is bound to the carrier via an antibody (for example, Hammerling et al., J. Exp. Med. 128: 1461-1473 (1968)).
- Bispecific antibodies used in diagnosing cancer are designed so that one arm of the antibody recognizes a tumor-associated antigen and the other is designed to bind to a detectable marker (eg, Le Doussal et al., Int. J. Cancer Suppl. 7: 58-62 (1992); Le Doussal et al. 3 J. Nucl. Med. 34: 1662-1671 (1993); Stickney et al., Cancer Res. 51: 6650-6655 (1991)).
- a detectable marker eg, Le Doussal et al., Int. J. Cancer Suppl. 7: 58-62 (1992); Le Doussal et al. 3 J. Nucl. Med. 34: 1662-1671 (1993); Stickney et al., Cancer Res. 51: 6650-6655 (1991)
- Multispecific antibodies can also be designed to elicit T cell killing effects (Shalaby et al., J. Exp. Med.
- multispecific antibodies can be used as fibrinolytics or vaccine adjuvants, for the treatment of infectious diseases (eg, targeting cells infected with HIV, influenza, protozoa), tumors, It can also be used to deliver antitoxins to cells and to activate immune complexes on cell surface receptors (Fanger et al., Supra).
- infectious diseases eg, targeting cells infected with HIV, influenza, protozoa
- tumors e.g, tumors, It can also be used to deliver antitoxins to cells and to activate immune complexes on cell surface receptors (Fanger et al., Supra).
- multispecific antibodies have been used for (1) chemical coupling of antibodies having different specificities with heterobifunctional linkers (Paulus, Behring Inst. Mitt., 78: 118-132 (1985)), (2) ) Fusion of hybridoma cells secreting different monoclonal antibodies (Millstein and 'Cuello, Nature 305: 537-539 (1983)), and (3) light and heavy chain genes of different monoclonal antibodies (four genes ) Into murine myeloma cells or other eukaryotic cell expression systems followed by isolation of the bispecific monovalent moiety (Zi Erman, Rev. Physio. Biochem. Pharmacol. 105: 176). -260 (1986); Van Dijk et al . :
- Diabody (Db) is a bivalent antibody fragment constructed by gene fusion (P. Holliger et al., Proc. Natl. Acad. Sci. USA 90: 6444-6448 (1993), EP 404,097, W093 / 11161, etc.).
- a diabody is a dimer composed of two polypeptide chains, each of which is a position where the light chain variable region (VL) and the heavy chain variable region (VH) cannot bind to each other in the same chain. It is linked by a short linker, for example, about 5 residues. VL and VH encoded on the same polypeptide chain cannot form a single-chain V region fragment (scFv) due to the short linker between them, and form a dimer.
- VL light chain variable region
- VH heavy chain variable region
- bispecific Db there are three types of assembling of the two types of chains, so that only 50% of the bispecific Db is obtained.
- VH and VL are linked with a linker of about 15 residues to display the antigen binding site as scFv.
- the length of the linker is required for the expression of the scFv. Complicated operations such as PCR assembling were necessary to change from a basic group to a linker with a length of about 5 residues enabling Db expression, and it was difficult to perform batch processing.
- the present invention provides a method for constructing a novel bispecific scDb library.
- VL and VH for two different antigens (a, b) are assigned in the order of VLa-VHb-VLb-VHa, with 15 remaining between VHb and VLb. It is expressed as a single chain that is linked by more than one group (however, the present invention is not limited to the order of the variable regions such as VLa, VHa, VLb, and VHb).
- a bispecific scDb library that expresses such a polypeptide chain (VLa-VHb-VLb-VHa) is -Can be created by batch processing from the library. That is, a gene in which nucleotides encoding two antibody variable regions (VLa and VHa) are linked by a linker having a restriction enzyme cleavage site, and a nucleotide encoding two antibody variable regions (VLb and VHb) are long.
- the present invention relates to a method for constructing such a bispecific scDb library, a gene usable in the method, a gene obtained by the method, an expression vector or an antibody library containing these genes, and the gene Which provides a peptide encoded by
- an antibody clone concentrated from a phage antibody library by panning or the like is used as a method for expressing VH and VL of scFv selected by binding to an antigen as a bispecific scDb by batch processing.
- an antibody clone concentrated from a phage antibody library by panning or the like is used as a method for expressing VH and VL of scFv selected by binding to an antigen as a bispecific scDb by batch processing.
- an antibody clone concentrated from a phage antibody library by panning or the like is used as a method for expressing VH and VL of scFv selected by binding to an antigen as a bispecific scDb by batch processing.
- an antibody clone concentrated from a phage antibody library by panning or the like is used as a method for expressing VH and VL of scFv selected by binding to an antigen as a bispecific scDb by batch processing.
- the first and second antibody variable regions and the third and fourth antibody variable regions are connected with a short linker, and the second and third antibody variable regions are connected with a long linker.
- the light chain variable region for the first antigen, the heavy chain variable region for the second antigen, the light chain variable region for the second antibody, and the heavy chain variable region for the first antigen are arranged in this order (10 ) Described gene,
- step (c) inserting the gene created in step (b) between the genes created in step (a),
- step (c) inserting the gene created in step (b) between the genes created in step (a),
- the method of the present invention is used to screen not only bispecific scDb but also monospecific scDb (for example, scDb that recognizes the same epitope but has variable regions having different sequences). It can also be applied to
- an antibody phage library is constructed by connecting VL-VH in order from the spleen of an animal immunized with antigen A and the like.
- the antibody phage library can be constructed according to a known method (for example, McCafferty et al., Nature 348: 552-554 (1990); C lackson et al., Nature 352: 624-628 (1991); Marks et al. 5 J. Mol. Biol. 222: 582-597 (1991)).
- Antigens for immunizing animals include complete immunogenic antigens and incomplete non-immunogenic antigens (including haptens). Substances composed of proteins, polypeptides, polysaccharides, nucleic acids, lipids and the like are mentioned as antigens, and in the present invention, the kind of substances constituting the antigen is not particularly limited.
- an immunogen used to immunize an animal a substance that can be an antigen in some cases can be bound to another molecule to be a soluble antigen, and a fragment thereof can be used in some cases.
- a transmembrane molecule such as a receptor
- cells expressing the transmembrane molecule on the cell surface can be used as an immunogen. Such cells can be of natural (such as tumor cell lines) or cells that have been constructed to express transmembrane molecules by recombinant techniques.
- Bispecific Db can be used in the same manner as a conventionally known bispecific antibody.
- one arm can be designed to recognize a tumor cell antigen, and the other arm can be designed to recognize a molecule that induces cytotoxicity.
- tumor cell antigens include, for example, CD15, pl85 HER2 , 1D10 (malignant B cells), p97, renal cell carcinoma, 0VCM-3, L-D1 (colorectal cancer), melanosite stimulating hormone analog, EGF receptor, CAMA1, MoV18, CD19, neural cell adhesion molecule (NCAM) ⁇ folate binding protein (FBP) ⁇ AMOC-31 (pan carcinoma assocated antigen), Id-1, CD22, CD7, CD38, CEA You can choose. Examples of molecules that induce cytotoxicity include FcaRI, CD16, and CD3. You.
- Db can be designed to bind to a toxin such as saponin, ricin A chain, IFN-hi, and vin alkaloid. Such bispecific Db is particularly useful in treating cancer.
- Bispecific Db is also useful as an agonist antibody.
- many site force-in receptors form homo- or hetero-dimers, and the distance and angle between the chains forming the dimer change when the ligand binds, resulting in intracellular changes. It is thought that the signal can be transmitted. Therefore, bispecific Db that binds to a receptor that forms such a dimer can mimic receptor dimerization by a ligand, and can be an agonist Db.
- Db that binds to CD30 and alkaline phosphatase and consequently involves enzymes that aid in the conversion of substances, such as Db that converts mitomycin phosphate to mitomycin alcohol.
- Db which can be used as a fibrinolytic agent, binds to fibrin, tPA, uPA, etc.
- Db which can be used as a fibrinolytic agent, binds to fibrin, tPA, uPA, etc.
- LDL and Fc receptors FcaRI, FcRII or FcaRIII
- Db that induces immune complexes to cell surface receptors (4) Db that can be used for infectious diseases that recognize antigens on T cells such as CD3 and antigens of pathogenic bacteria such as HCV, influenza and HIV (5) Db capable of binding to a detectable substance such as E0TUBE, DPTA, hapten, etc., and (6) Db (Fanger et al. 5 Crit. Rev.) which can be used as a vaccine adjuvant. Immunol. 12: 101-124 (1992)) and (7) may be used in diagnostics.
- Detectable substances such as ⁇ egret IgG, horseradish peroxidase (HRP), FITC, ⁇ -galactosidase, and Db with antigens such as hormones, ferritin, somatosustin, substance P, CEA, etc. .
- the Db of the present invention is not limited to these.
- the appropriate mammal is then immunized with the antigen.
- animals such as mice, hamsters, or rhesus monkeys can be used for immunization.
- lymphocytes can be immunized in vitro.
- DNA encoding the antibody contained in the spleen or lymphocytes of the immunized animal is purified by a conventional method (for example, antibody weighting).
- the H chain and L chain variable regions refer to a portion of the H chain and L chain of an immunoglobulin which usually consists of about 110 amino acids from the N-terminus.
- Immunoglobulins are divided into different classes (IgA, IgD, IgE, IgG, and IgM), which are further subclassed (isotyped) (eg, IgG-1, IgG2, IgG-3, and IgG-4, And IgA-1, and IgA-2), but the H chain and L chain variable regions of the present invention may belong to any of these classes and subclasses, and are not particularly limited.
- the antibody variable region of the present invention may be a shorter or modified antibody fragment as long as it has a binding property to a desired antigen.
- An “Fv” fragment is the smallest antibody fragment and contains a complete antigen-recognition and binding site.
- This region is a dimer in which the variable regions of one H chain and L chain are strongly linked by non-covalent bonds.
- the three complementarity determining regions (hypervariable regions; CDRs) present in each variable region interact to form an antigen-binding site on the surface of the dimer. That is, the six CDRs, including the H chain and the L chain, function as antigen-binding sites of the antibody.
- the antibody variable region constituting Db in the present invention is particularly preferably, but not limited to, an Fv fragment, and is capable of recognizing and binding to an antigen in which an H chain or L chain CDR is conserved. Any area is acceptable.
- variable regions of the present invention also include modified variable regions such as humanized.
- variable regions can be modified to improve the biological properties of the antibody, such as binding to an antigen.
- modification can be performed by site-specific mutation (see Kunkel, Proc. Nat 1. Acad. Sci. USA 82: 488 (1985)), PCR mutation, cassette mutation, and the like.
- antibody variants with improved biological properties are derived from amino acid sequence homology and similarity of 70% or more, more preferably 80% or more, and even more preferably 90% or more (eg, 95% or more). With the amino acid sequence of the variable region of the H or L chain.
- the homology and similarity of the sequence are determined by aligning the sequence as necessary so that the sequence homology takes the maximum value, introducing a gap, and then homologous (same as the original antibody residue). Residues) or similar (amino acid residues that fall into the same group based on the properties of common amino acid side chains).
- natural amino acid residues are (1) hydrophobic: norleucine, methionine, alanine, valine, leucine and isoloicin, (2) neutral hydrophilicity: cysteine, serine, threonine, asparagine and glutamine, (3) acidic: Aspartic acid and glutamic acid, (4) basicity: histidine, lysine, and arginine; (5) residues that affect chain orientation: glycine and proline; and (6) aromaticity: tributofan, tyrosine, and phenylalanine.
- the amino acids are classified into groups based on the properties of the side chains of each amino acid.
- the isolated heavy and light chain DNAs are linked using a linker of about 20 residues in length, and Into a phage library to create a phage library ⁇ At this time, the recognition sequence of the restriction enzyme BainHI, Acc III, etc. . Keep arranged Such linker one may be exemplified those having a sequence such as follows: BamHI AccI II
- GlyGlyGlyGlyGlyGlySerGlyGlyGlyGlySerGlyGlyGlyGlyGlySerGlyGlyGlyGlyGlyGlySerGlyGlyGlyGlyGlySer (SEQ ID NO: 2) Xbal ⁇ Aatl ⁇ Bell ⁇ BstEI I ⁇ Ehel ⁇ Kpnl, Nhel, Pstl ⁇ PvuI I, Sfil, Bgl Hael K K Hhal, HpaI I, Xhol and the like.
- the phages constituting the phage library include G4 phage, M13 phage, fd phage, fl phage, phage, T4 phage, T7 phage, P1, phage MS2, phage ⁇ , phage ⁇ 174, AgWES, Eb, Charon 4A, Charon30, and the like.
- an animal or lymphocyte is immunized with an antigen different from antigen A or with the same antigen (for example, when the epitope is different), and DNA encoding the heavy or light chain of the antibody is isolated.
- An antibody phage library is constructed by linking VH-VL in order using a linker approximately the length of residues. At this time, the 5 'end of VHb, and the VLb of VLb were inserted so that the genes encoding VHb and VLb binding to antigen B could be inserted between the genes encoding VLa and VHa binding to antigen A. Provide a sequence recognized by the restriction enzyme at the 3 'end.
- a library for antigen A is constructed by arranging a recognition sequence such as restriction enzyme BamHK AccI II, BamHI is arranged at the 5 ′ end of VH, and AccI II is arranged at the 3 and end of VL. Keep it.
- the phage library or a gene containing a variable region prepared from the phage library for example, a phagemid of each library concentrated by panning or the like (for example, Vaughan et al., Nature Biotechnolog 14) : 309-314
- a library of discDb can be constructed.
- the “linker” is not particularly limited as long as it does not inhibit the expression of an antibody variable region linked to both ends, and may or may not have a restriction enzyme cleavage site.
- the “long linker” refers to a linker having a length displayed as scFv when the H chain variable region and the L chain variable region of an antibody are expressed on a phage library by linking the linker. Means that.
- the chain length is not particularly limited, but is preferably 30 to; I50 bp, more preferably 36 to 90 bp, and particularly preferably 45 to 60 bp.
- short linker means a linker that forms a dimer (diabody: Db) when expressed by connecting the variable region of the H chain and the variable region of the L chain of the antibody with the linker.
- the chain length is not particularly limited, but preferably has a chain length of 6 to 27 bp, more preferably has a chain length of 9 to 21 bp, and particularly preferably has a chain length of 12 to L8 bp. .
- VLa-VHb-VLb-VHa was cut out by providing an appropriate restriction enzyme recognition site on the opposite side of the linker encoding the genes encoding VLa and VHa, and an appropriate expression vector was obtained.
- the gene encoding the target Db can be screened using the biological activity as an index. For example, when BamHI and AccIII are used in a fuzzy antibody library against antigens A and B as described above, appropriate expression using another restriction enzyme such as Sfil as shown in FIG. It can be inserted into a vector.
- Examples of the biological activity used as an index include an activity of specifically binding to an antigen, and depending on the type of antigen, an inhibitory activity, an agonist activity, an engonist activity, and the like are also included.
- a biscDb library constructed using an antibody library for cytokine receptors is inserted into a vector such as a retrovirus vector, Agonist biDb can be selected for by infecting cell-dependent proliferating cells.
- Procedures for constructing an expression system for expressing the Db of the present invention and construction of a recombinant vector suitable for a host can be carried out using a conventional technique in the field of genetic engineering (for example, Sambrook et al. 5 Molecular Cloning, Cold Spring Harb or Labolatories (1989), etc.).
- a conventional technique in the field of genetic engineering for example, Sambrook et al. 5 Molecular Cloning, Cold Spring Harb or Labolatories (1989), etc.
- the host cell any cells that can express the Db of the present invention, such as prokaryotes such as bacteria and eukaryotic cells such as yeast, animal cells, insect cells, and plant cells, can be used.
- mammalian cells are preferable from the viewpoint of glycosylation.
- the expression vector must include units for controlling the transcription and translation of genetic information, such as a promoter and a unit.
- a promoter for example, when a microorganism of the genus Escherichia such as Escherichia coli is used as a host cell, pBR and pUC-based plasmids can be used as plasmids, and lac, trp, tac, trc, phage PL, PR, etc. Promos from the United States are available.
- one-minute and one-minute one derived from trpA, one derived from phage, and one derived from rrnB ribosomal RNA can be used as the one-minute and one-minute.
- plasmids such as pUBllO and pC194 are known, and in some cases, the gene can be integrated into a chromosome.
- Promo One Night 'One Min One Night One can be derived from apr, npr, amy, etc.
- Other prokaryotic cells include genus Pseudomonas (eg, Pseudomonas putida,
- Brevibacterium eg, Brevibacterium lactofermentum; pAJ43, etc.
- Corynebacterium eg, Corynebacterium glutamicum, etc .; pCSll, pCBlOl, etc.
- Plasmid isolated from Lactococcus (Rhodococcus rhodochrous, etc.) (J. Gen. Microbiol. 138: 1003 (1992)
- Streptococcus pHV1301, pGKl, etc.
- Streptomyces genus for example, Streptomyces lividans, S.
- a system using Saccharomyces cerevisiae as a host and using YRp, YEp, YCp, and Yip plasmids is known.
- promoters such as ADH, GAPDH, PHOs GALs PGK, and ENO can be used.
- the genus Kleiberomyces eg, Kluyveromyces lactis, etc .; plasmids such as 2m, pKDl, pGKIl, KMS, etc.
- the genus Shizosa ⁇ caromyces eg, Schiz osaccharomyces pombe, etc .; pAUR224, etc.
- Genus eg, Zygos accharomyces rouxii, etc .; pSB3 and PH05 promoter derived from S.
- Genus Candida e.g., Candida laltosa, Candida tropical is, Can dida utilis, Candida albicans, etc.
- genus Aspereginoles e.g., E.g., Trichoderma rees ei
- E.g., Trichoderma rees ei can be used in the expression vector system of the present invention.
- plant cells can be used as hosts.
- plant cells derived from cotton, corn, potato, tomato, soybean, petunia, and tobacco can be used as hosts.
- a system using cells derived from Nicotina tabacum is known, which may be cultured in callus.
- the vector is introduced into a bacterium such as Agrobacterium tumefaciens using an expression vector such as PM0N530.
- this bacterium is transmitted to tobacco (for example, Nicotina ta bacum), the desired polypeptide can be obtained from tobacco leaves and the like.
- Silkworm Bactyx mori eight force (Aede aegypti, Aedes albopictus) N Sho jaw Bruno, 'E (Drosophila melanogaster) c for example insect cells can also be used as hosts, such as the case of using silkworms, a DNA encoding Db By inserting the virus into a baculovirus vector and infecting the silkworm with the virus, (Nature 315: 592-594 (1985)).
- promoters include promoters and enhancers for the cytomegalovirus IE gene, early promoter for SV40, and LTRs for retroviruses such as RSV, HIV and MMLV. And promoters of genes derived from animal cells such as metallothionein-actin, elongation factor 1, HSP, etc.
- viral vectors as described above Examples of viral vectors include DNA and RNA of retrovirus, adenovirus, adeno-associated virus, herpes virus, vaccinia virus, box virus, simbis virus, Sendai virus, SV40, HIV, etc. Viruses.
- Animal cell hosts include mouse myeloma cells (e.g., SP2 / 0, NS0, etc.), rat myeloma cells (e.g., YB2 / 0, etc.), mouse'hypridoma cells, Nmalwa cells (KJM -1 cells, etc.), human embryonic kidney cells (293 cells, etc.), human leukemia cells (BALL-1, etc.), CH0 cells, COS cells (C0S-1, C0S-7, etc.), hamster embryonic kidney cells ( BHK, etc.), mouse Sertoli cells (TM4, etc.), African green monkey kidney cells (VER0-76, etc.), HBT637 cells, HeLa cells, egret kidney cells (MDCK, etc.), human liver cells (HepG2, etc.), mouse breast cancer cells (MMT060562 cells), TRI cells, MRC cells, 'FS3 cells and the like.
- mouse myeloma cells e.g., SP2 / 0, NS0, etc.
- the method for introducing the expression vector depends on the type of the host and the vector, and any method can be used as long as it can introduce DNA encoding Db into cells.
- the method of introducing a vector into prokaryotic cells is to use calcium ions USA (Proc. Natl. Acad. Sci. USA 69: 2110 (1972)), the protoplast method (Japanese Patent Publication No. 63-24829), the electroporation method (Gene 17: 107 (1982); Molecular & General Genetics 168). : 111 (1979)) and the like; examples of the method of introduction into yeast include the electoporation method (Methods in Enzymology, 194: 182 (1990)) and the spheroplast method (Proc.
- the transformant obtained as described above can be cultured, for example, by the following method.
- the medium contains substances necessary for the growth of the carbon source, nitrogen source, inorganic salts, and the like that can be utilized by the organism, and the efficient culture of the transformant
- Either a natural medium or a synthetic medium may be used as long as it enables the above.
- the cultivation may be carried out under aerobic or anaerobic conditions, and conditions such as the growth temperature, the pH of the medium, and the growth time can be appropriately determined by those skilled in the art according to the type of the transformant used. is there.
- the expression vector using an inducible promoter it is possible to add an Indian user to the medium as needed (for example, IPTG for lac promoter, IAA for trp promoter, etc.). ).
- the culture medium is TNM-FH medium (Pharmin gen) ⁇ Sf-900 II SFM medium (Life Technologies), ExCel 1400 and ExCel 1405 (JRH Biosciences) ⁇ Grace's Insect Medium (Nature 195) : 788 (1962)) and the like, and if necessary, an antibiotic such as genyumycin may be added.
- the transformant is an animal cell
- commonly used RPMI1640 medium The Journal of American Medical Association 199: 519 (1967)
- Eagle's banded medium Science 122: 501 (1952)
- DMEM Medium Virology 8: 396 (1959)
- 199 medium Proceeding of the Society for the Biological Medicine 73: 1 (1950)
- the culture can be performed under normal conditions, for example, at pH 6 to 8, 30 to 40 °, and 5% CO 2 .
- an antibiotic such as kanamycin or penicillin may be added to the medium (the Db of the present invention thus obtained is secreted into host cells or extracellularly by using a signal sequence).
- the Db of the present invention thus obtained is secreted into host cells or extracellularly by using a signal sequence.
- an antibiotic such as kanamycin or penicillin
- it can be isolated from the medium, etc. and purified as a substantially pure polypeptide.
- the separation and purification of polypeptides are commonly used in chromatography, filters, ultrafiltration. , Salting out, solvent precipitation, solvent extraction, distillation, immunoprecipitation, SDS-polyacrylamide gel electrophoresis, isoelectric focusing, dialysis, recrystallization, etc.
- Chromatography includes affinity chromatography, ion exchange chromatography, hydrophobic chromatography, gel filtration, Antibodies: reverse phase chromatography, adsorption chromatography, etc.
- chromatographies can be carried out using liquid phase chromatography such as HPLC and FPL C. Since Db binds to an antigen, it can be purified using its binding property to the antigen.
- the present invention can be used in the above-described method for producing the scDb library.
- a linker encoding two antibody variable regions, wherein one of the variable regions and the other variable region have a restriction enzyme cleavage site.
- two antibodies available It relates to a gene encoding a variable region and having restriction enzyme cleavage sites added to both ends.
- the variable regions of the genes used as materials in the production of the scDb library of the present invention are preferably such that the heavy chain variable region and the light chain variable region are linked by a long linker so as to be expressed as scFv. Things.
- genes of (I) and (II) or the antibody library containing the genes are treated with restriction enzymes and ligated to encode the four antibody variable regions of the present invention.
- Genes having restriction enzyme cleavage sites between the second antibody variable region and between the third antibody variable region and the fourth antibody variable region can be obtained.
- a short linker is used between the first and second antibody variable regions and between the third and fourth antibody variable regions, and a long linker is used between the second and third antibody variable regions.
- the first is the heavy chain variable region for the first antigen
- the second is the light chain variable region for the second antigen
- the third is the heavy chain variable region for the second antigen
- the fourth is If the light chain variable regions for the first antigen are arranged in this order, a bispecific single chain diabody can be obtained when this is expressed.
- the present invention includes a vector and a library containing such a gene, and a peptide encoded by the gene.
- the present invention also provides
- the present invention also provides a method for preparing an antibody library or an expression vector comprising: According to this method, the method for producing the scDb library of the present invention can be applied to monospecific Db.
- the following BaMil site (underlined) is provided in the linker at the time of constructing a phage library.
- GlyGlyGlyGlyGlyGlySerGlyGlyGlyGlyGlySerGlyGlyGlyGlyGlyGlyGlyGlyGlyGlyG SerGlyGlyGlyGlySer (SEQ ID NO: 3)
- GGTGGTGGT6GATCCGGTGGTGGTGGTTCTGGCGGCGGCGGCTCCGGAGCGGCGGCTCCGGAGGTGGTGGATCC (SEQ ID NO: 4) Phagemid or a gene amplified from the above phage library using PCR) is treated with BamHI and self-cyclized to reduce the linker length from 20 residues for scFv to 5 residues optimal for diabody.
- the VL-VH fragment containing the receptor-binding antibody thus produced is inserted into an appropriate expression vector to achieve biological activity. For example, by inserting a Db library constructed using a cytokine receptor antibody library into a retrovirus vector and infecting target cytokine-dependent proliferating cells, The agonist Db can be selected.
- the scDb of the present invention is useful in clinical fields such as immunodiagnosis, treatment, and diagnosis by immunoassay, as with conventionally known multispecific antibodies.
- immunoassay for example, to induce cytotoxicity such as killing tumor cells, etc., as a vaccine adjuvant, to properly deliver drugs such as thrombolytic agents to the target in vivo, to be activated by enzymes
- drugs such as thrombolytic agents
- to be activated by enzymes In order to reliably convert prodrugs to be converted at target sites, to treat infectious diseases, and to induce immune complexes with cell surface receptors, to target immunotoxins and other target cells such as tumor cells
- Various therapeutic purposes are conceivable, such as for transportation to a hospital.
- the pharmaceutical composition containing Db of the present invention used for such a therapeutic purpose may be formulated as necessary by mixing with a suitable pharmaceutically acceptable carrier, medium or the like which is inactive against them. can do.
- a suitable pharmaceutically acceptable carrier for example, sterile water or physiological saline, stabilizers, excipients, antioxidants (ascorbic acid, etc.), buffers (phosphoric acid, citric acid, other organic acids, etc.), preservatives, surfactants (PEG , Tween etc.), chelating agent (EDTA etc.), c can be given binding agent also other low molecular weight polypeptides, serum albumin, gelatin and immune Glo purine proteins such as glycine, glutamine, Asuparagin, arginine It may contain amino acids such as ricin, sugars such as polysaccharides and monosaccharides, carbohydrates, and sugar alcohols such as mannitol and sorbitol.
- aqueous solution for injection for example, physiological saline, isotonic solution containing glucose and other adjuvants, such as D-sorbitol, D-mannose, D-mannitol, and sodium chloride, are suitable.
- the Db of the present invention may be encapsulated in microcapsules (microcapsules of hydroxymethylcellulose, gelatin, poly [methylmethacrylic acid], etc.), and colloid drug delivery systems (ribosome, albumin microsphere, micro Emar Ji may be a nano-particles, and nano-capsules) ( "Remi ngton 's Pharmaceutical Science 16 th edition", Oslo Ed. (1980)).
- a method of converting a drug into a sustained-release drug is also known and can be applied to the Db of the present invention (Langer et al., J. Biomed. Mater. Res. 15: 167-277 (1981); Langer, chem.Tech. 12: 98-105 (1982); U.S. Patent No. 3,773,919; European Patent Application Publication (EP) No. 58,481; Sidman et al., Biopolymers 22: 547-556 (1983) ); EP 133, 988).
- Administration to the patient is preferably by injection or infusion, for example, by intra-arterial injection,
- intra-arterial injection In addition to intravenous injection, subcutaneous injection, etc., intranasal, transbronchial, intramuscular, transdermal or oral routes can be used to carry out the method known to those skilled in the art.
- the dose varies depending on various factors such as the patient's body weight, age, type of disease, symptoms, administration method and the like, and those skilled in the art can appropriately select an appropriate dose.
- the administration method includes direct administration using naked plasmid, packaging in ribosome, retrovirus vector, adenovirus vector, vaccinia virus vector, box virus vector, adenovirus-related vector, HVJ vector, etc. (See Adolph “Viral Genome Method”, CRC Press, Florid (1996)) or coated on bead carriers such as colloidal gold particles (W093 / 17706 etc.) for administration can do. However, it may be administered by any method as long as Db is expressed in vivo and exerts its action.
- injection, infusion, or gas-induced particle bombardment (intravenous, intraperitoneal, subcutaneous, intradermal, intradermal, adipose tissue, intramammary tissue, inhalation or intramuscular routes)
- a sufficient amount is administered by an electron gun or the like, or via a mucosal route such as a nasal drug). ex) to blood cells and bone marrow-derived cells, etc., using ribosome transfection, particle bombardment (U.S. Pat. No. 4,945,050), or viral infection, and the cells are administered to animals.
- the gene encoding Db of the present invention may be administered by re-introduction.
- the Db of the present invention can also be used for enzyme immunoassay.
- one antibody variable region of Db is designed to recognize an epitope that does not inhibit enzyme activity on the enzyme, and the other is to recognize a carrier that binds to the carrier.
- Db which recognizes IgG, ferritin, HRP, hormone and the like can be mentioned.
- the Db of the present invention can also be used for immunodiagnosis of various diseases in i / 2 vivo and in vitro.
- one of the antibody variable regions of Db is designed to recognize an antigen specific to tumor cells, and the other is designed to bind to a detectable marker. can do.
- Radioisotopes as detectable Ma one force one e.g., 3 ⁇ 4, 14 C, 32 P , 35 S, 125 1 , etc.
- fluorescent dyes Fluoresein, luciferin, etc.
- chemical Ruminesen scan compound I Seo thio Xia sulfonates , Rhodamine, etc.
- alkaline phosphatase -galactosidase
- HRP horseradishin
- Binding and detection of Db with these substances can be carried out according to known methods (Hunter, etc.). et al., Natur e 144: 945 (1962); David et al., Biochemistry 13: 1014 (1974); Pain et al., J. Immunol. Me th. 40: 219 (1981); Nygen, J. Histochem and Cytochem 30: 407 (1982)).
- the Db of the present invention having reactivity to a detectable substance as described above can be used for competitive binding analysis, direct and indirect sandwich immunoassay (ELISA etc.), immunoprecipitation assay (Zola, "Monoclonal Antibodies: A Manual of Techniques ", pp. 147-158, CRC Press Inc. (1987)) and the like.
- ELISA etc. sandwich immunoassay
- Zola immunoprecipitation assay
- FIG. 1 is a diagram schematically showing a method for constructing a bispecific scDb library for antigens A and B.
- FIG. 2 is a diagram schematically showing a method for constructing a Db library from a phage antibody library.
- the present invention provides a method for constructing a novel bispecific scDb library.
- a bispecific scDb library can be prepared from a scFv phage library by a batch processing without complicated processing.
- the present invention also provides a method for collectively transferring an antibody clone concentrated from a phage antibody library by panning or the like to an expression vector for animal cells.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Bioinformatics & Computational Biology (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Liquid Crystal Substances (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Automatic Tape Cassette Changers (AREA)
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003227504A AU2003227504A1 (en) | 2002-04-15 | 2003-04-15 | METHOD OF CONSTRUCTING scDb LIBRARY |
AT03717592T ATE512989T1 (de) | 2002-04-15 | 2003-04-15 | Verfahren zur herstellung von scdb-bibliotheken |
US10/510,971 US8030461B2 (en) | 2002-04-15 | 2003-04-15 | Methods for constructing scDb libraries |
JP2003584118A JP4386741B2 (ja) | 2002-04-15 | 2003-04-15 | scDbライブラリーの作成方法 |
EP03717592A EP1500665B1 (en) | 2002-04-15 | 2003-04-15 | METHODS FOR CONSTRUCTING scDb LIBRARIES |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002-112369 | 2002-04-15 | ||
JP2002112369 | 2002-04-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003087163A1 true WO2003087163A1 (fr) | 2003-10-23 |
Family
ID=29243316
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/004773 WO2003087163A1 (fr) | 2002-04-15 | 2003-04-15 | Procede d'elaboration d'une banque scdb |
Country Status (6)
Country | Link |
---|---|
US (1) | US8030461B2 (ja) |
EP (1) | EP1500665B1 (ja) |
JP (1) | JP4386741B2 (ja) |
AT (1) | ATE512989T1 (ja) |
AU (1) | AU2003227504A1 (ja) |
WO (1) | WO2003087163A1 (ja) |
Cited By (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8030461B2 (en) | 2002-04-15 | 2011-10-04 | Chugai Seiyaku Kabushiki Kaisha | Methods for constructing scDb libraries |
US8062635B2 (en) | 2003-10-10 | 2011-11-22 | Chugai Seiyaku Kabushiki Kaisha | Bispecific antibody substituting for functional proteins |
US8337841B2 (en) | 2003-01-21 | 2012-12-25 | Chugai Seiyaku Kabushiki Kaisha | Methods of screening for antibody light chains |
US8597911B2 (en) | 2003-06-11 | 2013-12-03 | Chugai Seiyaku Kabushiki Kaisha | Process for producing antibodies |
US8945543B2 (en) | 2005-06-10 | 2015-02-03 | Chugai Seiyaku Kabushiki Kaisha | Stabilizer for protein preparation comprising meglumine and use thereof |
US9241994B2 (en) | 2005-06-10 | 2016-01-26 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical compositions containing sc(Fv)2 |
US9334331B2 (en) | 2010-11-17 | 2016-05-10 | Chugai Seiyaku Kabushiki Kaisha | Bispecific antibodies |
US9493569B2 (en) | 2005-03-31 | 2016-11-15 | Chugai Seiyaku Kabushiki Kaisha | Structural isomers of sc(Fv)2 |
US9670269B2 (en) | 2006-03-31 | 2017-06-06 | Chugai Seiyaku Kabushiki Kaisha | Methods of modifying antibodies for purification of bispecific antibodies |
US9828429B2 (en) | 2007-09-26 | 2017-11-28 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in CDR |
US9975966B2 (en) | 2014-09-26 | 2018-05-22 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing theraputic agent |
US10011858B2 (en) | 2005-03-31 | 2018-07-03 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
US10759870B2 (en) | 2017-09-29 | 2020-09-01 | Chugai Seiyaku Kabushiki Kaisha | Multispecific antigen-binding molecules having blood coagulation factor VIII (FVIII) cofactor function-substituting activity and pharmaceutical formulations containing such a molecule as an active ingredient |
US11046784B2 (en) | 2006-03-31 | 2021-06-29 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
US11124576B2 (en) | 2013-09-27 | 2021-09-21 | Chungai Seiyaku Kabushiki Kaisha | Method for producing polypeptide heteromultimer |
US11142587B2 (en) | 2015-04-01 | 2021-10-12 | Chugai Seiyaku Kabushiki Kaisha | Method for producing polypeptide hetero-oligomer |
US11150254B2 (en) | 2014-09-26 | 2021-10-19 | Chugai Seiyaku Kabushiki Kaisha | Method for measuring reactivity of FVIII |
US11214623B2 (en) | 2014-09-26 | 2022-01-04 | Chugai Seiyaku Kabushiki Kaisha | Antibody capable of neutralizing substance having activity alternative to function of coagulation factor VIII (FVIII) |
US11352438B2 (en) | 2016-09-06 | 2022-06-07 | Chugai Seiyaku Kabushiki Kaisha | Methods of using a bispecific antibody that recognizes coagulation factor IX and/or activated coagulation factor IX and coagulation factor X and/or activated coagulation factor X |
US11649262B2 (en) | 2015-12-28 | 2023-05-16 | Chugai Seiyaku Kabushiki Kaisha | Method for promoting efficiency of purification of Fc region-containing polypeptide |
Families Citing this family (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1561759B9 (en) * | 2002-10-11 | 2009-08-26 | Chugai Seiyaku Kabushiki Kaisha | Cell death-inducing agent |
AU2003271186A1 (en) * | 2003-10-14 | 2005-04-27 | Chugai Seiyaku Kabushiki Kaisha | Double specific antibodies substituting for functional protein |
TW200530269A (en) * | 2003-12-12 | 2005-09-16 | Chugai Pharmaceutical Co Ltd | Anti-Mpl antibodies |
JPWO2005056605A1 (ja) * | 2003-12-12 | 2007-12-06 | 中外製薬株式会社 | 3量体以上の受容体を認識する改変抗体 |
AU2004297109A1 (en) * | 2003-12-12 | 2005-06-23 | Chugai Seiyaku Kabushiki Kaisha | Cell death inducing agent |
JPWO2005056602A1 (ja) * | 2003-12-12 | 2008-03-06 | 中外製薬株式会社 | アゴニスト活性を有する改変抗体のスクリーニング方法 |
EP1757686A4 (en) * | 2004-04-09 | 2008-03-12 | Chugai Pharmaceutical Co Ltd | INDUCER OF CELL DEATH |
CA2957144C (en) * | 2005-04-08 | 2020-06-02 | Chugai Seiyaku Kabushiki Kaisha | Antibody substituting for function of blood coagulation factor viii |
JP5224580B2 (ja) * | 2005-06-10 | 2013-07-03 | 中外製薬株式会社 | sc(Fv)2部位特異的変異体 |
CL2007002057A1 (es) * | 2006-07-13 | 2008-01-11 | Chugai Pharmaceutical Co Ltd | Diacuerpo anti-antigeno leucocitario humano (hla), usos del diacuerpo para preparar un medicamento util como inductor de muerte celular, supresor del crecimeinto celular o como agente antitumoral. |
AU2008328779B2 (en) | 2007-11-27 | 2014-06-05 | Ablynx N.V. | Amino acid sequences directed against HER2 and polypeptides comprising the same for the treatment of cancers and/or tumors |
EP2361936B1 (en) * | 2010-02-25 | 2016-04-20 | Affimed GmbH | Antigen-binding molecule and uses thereof |
RU2613368C2 (ru) * | 2011-07-22 | 2017-03-16 | Аффимед Гмбх | Поливалентная антиген-связывающая fv-молекула |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
TWI777174B (zh) | 2014-03-14 | 2022-09-11 | 瑞士商諾華公司 | 針對lag-3之抗體分子及其用途 |
US20170335281A1 (en) | 2014-03-15 | 2017-11-23 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
WO2016001810A1 (en) | 2014-07-01 | 2016-01-07 | Pfizer Inc. | Bispecific heterodimeric diabodies and uses thereof |
KR102612313B1 (ko) | 2014-07-21 | 2023-12-12 | 노파르티스 아게 | 인간화 항-bcma 키메라 항원 수용체를 사용한 암의 치료 |
WO2016014530A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Combinations of low, immune enhancing. doses of mtor inhibitors and cars |
US11542488B2 (en) | 2014-07-21 | 2023-01-03 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
CN112481283A (zh) | 2014-07-21 | 2021-03-12 | 诺华股份有限公司 | 使用cd33嵌合抗原受体治疗癌症 |
ES2781175T3 (es) | 2014-07-31 | 2020-08-31 | Novartis Ag | Subconjunto optimizado de células T que contienen un receptor de antígeno quimérico |
US10851149B2 (en) | 2014-08-14 | 2020-12-01 | The Trustees Of The University Of Pennsylvania | Treatment of cancer using GFR α-4 chimeric antigen receptor |
JP7084138B2 (ja) | 2014-08-19 | 2022-06-14 | ノバルティス アーゲー | 癌処置に使用するための抗cd123キメラ抗原受容体(car) |
CN114621969A (zh) | 2014-09-17 | 2022-06-14 | 诺华股份有限公司 | 用于过继免疫疗法的具有嵌合受体的靶向细胞毒性细胞 |
MA40035A (fr) | 2014-10-14 | 2016-04-21 | Dana Farber Cancer Inst Inc | Molécules d'anticorps de pd-l1 et leurs utilisations |
US20180334490A1 (en) | 2014-12-03 | 2018-11-22 | Qilong H. Wu | Methods for b cell preconditioning in car therapy |
CN114958764A (zh) | 2015-04-08 | 2022-08-30 | 诺华股份有限公司 | Cd20疗法、cd22疗法和与cd19嵌合抗原受体(car)表达细胞的联合疗法 |
EP3286211A1 (en) | 2015-04-23 | 2018-02-28 | Novartis AG | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
PT3317301T (pt) | 2015-07-29 | 2021-07-09 | Novartis Ag | Terapias de associação compreendendo moléculas de anticorpo contra lag-3 |
EP3878465A1 (en) | 2015-07-29 | 2021-09-15 | Novartis AG | Combination therapies comprising antibody molecules to tim-3 |
CA3007421A1 (en) | 2015-12-17 | 2017-06-22 | Novartis Ag | Combination of c-met inhibitor with antibody molecule to pd-1 and uses thereof |
WO2017106656A1 (en) | 2015-12-17 | 2017-06-22 | Novartis Ag | Antibody molecules to pd-1 and uses thereof |
MA55746A (fr) | 2016-01-21 | 2022-03-02 | Novartis Ag | Molécules multispécifiques ciblant cll-1 |
CA3016287A1 (en) | 2016-03-04 | 2017-09-08 | Novartis Ag | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore |
WO2017165683A1 (en) | 2016-03-23 | 2017-09-28 | Novartis Ag | Cell secreted minibodies and uses thereof |
PL3443096T3 (pl) | 2016-04-15 | 2023-06-19 | Novartis Ag | Kompozycje i sposoby do selektywnej ekspresji chimerycznych receptorów antygenowych |
US20210177896A1 (en) | 2016-06-02 | 2021-06-17 | Novartis Ag | Therapeutic regimens for chimeric antigen receptor (car)- expressing cells |
EP3484455A2 (en) | 2016-07-15 | 2019-05-22 | Novartis AG | Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor |
CN118021943A (zh) | 2016-07-28 | 2024-05-14 | 诺华股份有限公司 | 嵌合抗原受体和pd-1抑制剂的组合疗法 |
KR20190036551A (ko) | 2016-08-01 | 2019-04-04 | 노파르티스 아게 | Pro-m2 대식세포 분자의 억제제를 병용하는, 키메라 항원 수용체를 이용한 암의 치료 |
AR110676A1 (es) | 2016-10-07 | 2019-04-24 | Novartis Ag | Tratamiento del cáncer utilizando receptores de antígenos quiméricos |
EP4043485A1 (en) | 2017-01-26 | 2022-08-17 | Novartis AG | Cd28 compositions and methods for chimeric antigen receptor therapy |
WO2018160731A1 (en) | 2017-02-28 | 2018-09-07 | Novartis Ag | Shp inhibitor compositions and uses for chimeric antigen receptor therapy |
EP3615068A1 (en) | 2017-04-28 | 2020-03-04 | Novartis AG | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
EP3615055A1 (en) | 2017-04-28 | 2020-03-04 | Novartis AG | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
AU2018290237A1 (en) | 2017-06-22 | 2020-01-16 | Novartis Ag | Antibody molecules to CD73 and uses thereof |
AU2018292618A1 (en) | 2017-06-27 | 2019-12-19 | Novartis Ag | Dosage regimens for anti-TIM-3 antibodies and uses thereof |
CN111278858A (zh) | 2017-07-11 | 2020-06-12 | 指南针制药有限责任公司 | 结合人cd137的激动剂抗体及其用途 |
US20200172617A1 (en) | 2017-07-20 | 2020-06-04 | Novartis Ag | Dosage regimens of anti-lag-3 antibodies and uses thereof |
US11718679B2 (en) | 2017-10-31 | 2023-08-08 | Compass Therapeutics Llc | CD137 antibodies and PD-1 antagonists and uses thereof |
WO2019089798A1 (en) | 2017-10-31 | 2019-05-09 | Novartis Ag | Anti-car compositions and methods |
KR20200089286A (ko) | 2017-11-16 | 2020-07-24 | 노파르티스 아게 | 조합 요법 |
EP3713961A2 (en) | 2017-11-20 | 2020-09-30 | Compass Therapeutics LLC | Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof |
US20210038659A1 (en) | 2018-01-31 | 2021-02-11 | Novartis Ag | Combination therapy using a chimeric antigen receptor |
US20210147547A1 (en) | 2018-04-13 | 2021-05-20 | Novartis Ag | Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof |
EP3784351A1 (en) | 2018-04-27 | 2021-03-03 | Novartis AG | Car t cell therapies with enhanced efficacy |
TW202003580A (zh) | 2018-05-21 | 2020-01-16 | 美商坎伯斯治療有限責任公司 | 用於增強nk細胞對標靶細胞之殺死之組合物及方法 |
WO2019226658A1 (en) | 2018-05-21 | 2019-11-28 | Compass Therapeutics Llc | Multispecific antigen-binding compositions and methods of use |
EP3801769A1 (en) | 2018-05-25 | 2021-04-14 | Novartis AG | Combination therapy with chimeric antigen receptor (car) therapies |
WO2019232244A2 (en) | 2018-05-31 | 2019-12-05 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
EP3806962A1 (en) | 2018-06-13 | 2021-04-21 | Novartis AG | Bcma chimeric antigen receptors and uses thereof |
US20210238268A1 (en) | 2018-06-19 | 2021-08-05 | Atarga, Llc | Antibody molecules to complement component 5 and uses thereof |
AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
WO2020021465A1 (en) | 2018-07-25 | 2020-01-30 | Advanced Accelerator Applications (Italy) S.R.L. | Method of treatment of neuroendocrine tumors |
CN113166269A (zh) | 2018-11-13 | 2021-07-23 | 指南针制药有限责任公司 | 对抗检查点分子的多特异性结合构建体及其用途 |
AU2019402189B2 (en) | 2018-12-20 | 2023-04-13 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
MX2021007391A (es) | 2018-12-20 | 2021-09-23 | Novartis Ag | Regimenes de baja dosis extendida para inhibidores de mdm2. |
KR20210129671A (ko) | 2019-02-15 | 2021-10-28 | 노파르티스 아게 | 3-(1-옥소-5-(피페리딘-4-일)이소인돌린-2-일)피페리딘-2,6-디온 유도체 및 이의 용도 |
EP3924055B1 (en) | 2019-02-15 | 2024-04-03 | Novartis AG | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
US10871640B2 (en) | 2019-02-15 | 2020-12-22 | Perkinelmer Cellular Technologies Germany Gmbh | Methods and systems for automated imaging of three-dimensional objects |
EP3927371A1 (en) | 2019-02-22 | 2021-12-29 | Novartis AG | Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors |
SG11202110732XA (en) | 2019-03-29 | 2021-10-28 | Atarga Llc | Anti fgf23 antibody |
BR112022007179A2 (pt) | 2019-10-21 | 2022-08-23 | Novartis Ag | Inibidores de tim-3 e usos dos mesmos |
TW202128166A (zh) | 2019-10-21 | 2021-08-01 | 瑞士商諾華公司 | 組合療法 |
JP2023503163A (ja) | 2019-11-26 | 2023-01-26 | ノバルティス アーゲー | キメラ抗原受容体及びその使用 |
EP4077389A1 (en) | 2019-12-20 | 2022-10-26 | Novartis AG | Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome |
CN114980902A (zh) | 2020-01-17 | 2022-08-30 | 诺华股份有限公司 | 用于治疗骨髓增生异常综合征或慢性粒单核细胞白血病的包含tim-3抑制剂和低甲基化药物的组合 |
CN115298322A (zh) | 2020-01-17 | 2022-11-04 | 贝克顿迪金森公司 | 用于单细胞分泌组学的方法和组合物 |
KR20220147109A (ko) | 2020-02-27 | 2022-11-02 | 노파르티스 아게 | 키메라 항원 수용체 발현 세포의 제조 방법 |
JP2023531676A (ja) | 2020-06-23 | 2023-07-25 | ノバルティス アーゲー | 3-(1-オキソイソインドリン-2-イル)ピぺリジン-2,6-ジオン誘導体を含む投与レジメン |
TW202216761A (zh) | 2020-07-16 | 2022-05-01 | 瑞士商諾華公司 | 抗β細胞素抗體、其片段及多特異性結合分子 |
WO2022026592A2 (en) | 2020-07-28 | 2022-02-03 | Celltas Bio, Inc. | Antibody molecules to coronavirus and uses thereof |
JP2023536164A (ja) | 2020-08-03 | 2023-08-23 | ノバルティス アーゲー | ヘテロアリール置換3-(1-オキソイソインドリン-2-イル)ピペリジン-2,6-ジオン誘導体及びその使用 |
WO2022043558A1 (en) | 2020-08-31 | 2022-03-03 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
EP4204021A1 (en) | 2020-08-31 | 2023-07-05 | Advanced Accelerator Applications International S.A. | Method of treating psma-expressing cancers |
US20240002509A1 (en) | 2020-11-06 | 2024-01-04 | Novartis Ag | ANTIBODY Fc VARIANTS |
CA3198447A1 (en) | 2020-11-13 | 2022-05-19 | Novartis Ag | Combination therapies with chimeric antigen receptor (car)-expressing cells |
EP4284510A1 (en) | 2021-01-29 | 2023-12-06 | Novartis AG | Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof |
TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途 |
AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
WO2023044483A2 (en) | 2021-09-20 | 2023-03-23 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
WO2023092004A1 (en) | 2021-11-17 | 2023-05-25 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
US20230383010A1 (en) | 2022-02-07 | 2023-11-30 | Visterra, Inc. | Anti-idiotype antibody molecules and uses thereof |
WO2023220695A2 (en) | 2022-05-13 | 2023-11-16 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
WO2024030976A2 (en) | 2022-08-03 | 2024-02-08 | Voyager Therapeutics, Inc. | Compositions and methods for crossing the blood brain barrier |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
EP0058481A1 (en) | 1981-02-16 | 1982-08-25 | Zeneca Limited | Continuous release pharmaceutical compositions |
EP0133988A2 (de) | 1983-08-02 | 1985-03-13 | Hoechst Aktiengesellschaft | Regulatorische Peptide enthaltende pharmazeutische Präparate mit protrahierter Freisetzung und Verfahren zu deren Herstellung |
US4945050A (en) | 1984-11-13 | 1990-07-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
WO1993017706A1 (en) | 1992-03-11 | 1993-09-16 | Agracetus, Inc. | Genetic vaccine for immunodeficiency viruses |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
AU5509296A (en) | 1995-05-03 | 1996-11-21 | Colin Henry Self | Bispecific antibodies in which the binding capability is rev ersibly inhibited by a photocleavable moiety |
ES2246069T3 (es) | 1997-05-02 | 2006-02-01 | Genentech, Inc. | Procedimiento de preparacion de anticuerpos multiespecificos que tienen componentes comunes y multimericos. |
DE19819846B4 (de) | 1998-05-05 | 2016-11-24 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Multivalente Antikörper-Konstrukte |
US6897044B1 (en) | 1999-01-28 | 2005-05-24 | Biogen Idec, Inc. | Production of tetravalent antibodies |
EP1238080A2 (en) | 1999-12-14 | 2002-09-11 | The Burnham Institute | Bcl-g polypeptides, encoding nucleic acids and methods of use |
DE60132075T2 (de) | 2000-03-22 | 2009-03-12 | Curagen Corp., New Haven | Wnt-1 verwandte polypeptide und dafür kodierende nukleinsäuren |
AU2002319402B2 (en) * | 2001-06-28 | 2008-09-11 | Domantis Limited | Dual-specific ligand and its use |
AU2003227504A1 (en) | 2002-04-15 | 2003-10-27 | Chugai Seiyaku Kabushiki Kaisha | METHOD OF CONSTRUCTING scDb LIBRARY |
WO2004065611A1 (ja) * | 2003-01-21 | 2004-08-05 | Chugai Seiyaku Kabushiki Kaisha | 抗体の軽鎖スクリーニング方法 |
WO2004111233A1 (ja) * | 2003-06-11 | 2004-12-23 | Chugai Seiyaku Kabushiki Kaisha | 抗体の製造方法 |
-
2003
- 2003-04-15 AU AU2003227504A patent/AU2003227504A1/en not_active Abandoned
- 2003-04-15 US US10/510,971 patent/US8030461B2/en not_active Expired - Fee Related
- 2003-04-15 WO PCT/JP2003/004773 patent/WO2003087163A1/ja active Application Filing
- 2003-04-15 JP JP2003584118A patent/JP4386741B2/ja not_active Expired - Fee Related
- 2003-04-15 EP EP03717592A patent/EP1500665B1/en not_active Expired - Lifetime
- 2003-04-15 AT AT03717592T patent/ATE512989T1/de not_active IP Right Cessation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
EP0058481A1 (en) | 1981-02-16 | 1982-08-25 | Zeneca Limited | Continuous release pharmaceutical compositions |
EP0133988A2 (de) | 1983-08-02 | 1985-03-13 | Hoechst Aktiengesellschaft | Regulatorische Peptide enthaltende pharmazeutische Präparate mit protrahierter Freisetzung und Verfahren zu deren Herstellung |
US4945050A (en) | 1984-11-13 | 1990-07-31 | Cornell Research Foundation, Inc. | Method for transporting substances into living cells and tissues and apparatus therefor |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
WO1993017706A1 (en) | 1992-03-11 | 1993-09-16 | Agracetus, Inc. | Genetic vaccine for immunodeficiency viruses |
Non-Patent Citations (37)
Title |
---|
ADOLPH: "Virus Genome Methods", 1996, CRC PRESS |
ANDRIS-WIDHOPF J. ET AL.: "Methods for the generation of chicken monoclonal antibody fragments by phage display", JOURNAL OF IMMUNOLOGICAL METHODS, vol. 242, 2000, pages 159 - 181, XP004210719 * |
CWIRLA ET AL., PROC. NATL. ACAD. SCI. USA, vol. 8, 1990, pages 309 |
DANIEL R. MARSHAK ET AL.: "Strategies for Protein Purification and Characterization: A Laboratory Course Manual", 1996, COLD SPRING HARBOR LABORATORY PRESS |
DAVID ET AL., BIOCHEMISTRY, vol. 13, 1974, pages 1014 |
DENARDO D.G. ET AL.: "Anti-HLA-DR/anti-DOTA diabody construction in modular gene design platform: bispecific antibodies for pretargeted radioimmunotherapy", CANCER BIOTHERAPY & RADIOPHARMACEUTICALS, vol. 16, no. 6, 2001, pages 525 - 535, XP008022084 * |
DEVLIN ET AL., SCIENCE, vol. 249, 1990, pages 404 |
HAMMERLING ET AL., J. EXP. MED., vol. 128, 1968, pages 1461 - 1473 |
HARLOW AND DAVID LANE: "Antibodies: A Laboratory Course Manual", 1988, COLD SPRING HARBOR LABORATORY PRESS |
HOLLIGER P. ET AL.: "Diabodies, small bivalent and bispecific antibody fragments", PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 6444 - 6448, XP002008022 * |
HUNTER ET AL., NATURE, vol. 144, 1962, pages 945 |
LANGER ET AL., J. BIOMED. MATER. RES., vol. 15, 1981, pages 167 - 277 |
LANGER, CHEM. TECH., vol. 12, 1982, pages 98 - 105 |
LE DOUSSAL ET AL., INT. J. CANCER SUPPL., vol. 7, 1992, pages 58 - 62 |
LE DOUSSAL ET AL., J. NUCL. MED., vol. 34, 1993, pages 1662 - 1671 |
MCGUINNESS B.T. ET AL.: "Phage diabody repertoires for selection of large number of bispecific antibody fragments", NATURE BIOTECHNOLOGY, vol. 14, no. 9, 1996, pages 1149 - 1154, XP002100039 * |
MCGUINNESS ET AL., NATURE BIOTECHNOLOGY, vol. 14, 1996, pages 1149 - 1154 |
NATURE, vol. 195, 1962, pages 788 |
NYGEN, J. HISTOCHEM. CYTOCHEM., vol. 30, 1982, pages 407 |
OSLO: "Remington's Pharmaceutical Science 16th edition", 1980 |
PAIN ET AL., J. IMMUNOL. METH., vol. 40, 1981, pages 219 |
PROCEEDING OF THE SOCIETY FOR THE BIOLOGICAL MEDICINE, vol. 73, 1950, pages 1 |
SCIENCE, vol. 122, 1952, pages 501 |
SCOTT; SMITH, SCIENCE, vol. 249, 1990, pages 386 |
SEGAL ET AL.: "Biologic Therapy of Cancer", vol. 2 |
SEGAL; SNIDER, CHEM. IMMUNOL., vol. 47, 1989, pages 179 - 213 |
SIDMAN ET AL., BIOPOLYMERS, vol. 22, 1983, pages 547 - 556 |
SMITH, SCIENCE, vol. 228, 1985, pages 1315 |
SONGSIVILAI ET AL., CLIN. EXP. IMMUNOL., vol. 79, 1990, pages 315 - 321 |
STICKNEY ET AL., CANCER RES., vol. 51, 1991, pages 6650 - 6655 |
TANG Y. ET AL.: "Selection of linkers for a catalytic single-chain antibody using phage display technology", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 26, 1996, pages 15682 - 15686, XP002962142 * |
THE JOURNAL OF AMERICAN MEDICAL ASSOCIATION, vol. 199, 1967, pages 519 |
TURNER D.J. ET AL.: "Importance of the linker in expression of single-chain Fv antibody fragments: optimization of peptide sequence using pohage display technology", JOURNAL OF IMMUNOLOGICAL METHODS, vol. 205, 1997, pages 43 - 54, XP004082109 * |
VIROLOGY, vol. 8, 1959, pages 396 |
VOLKEL ET AL., PROT. ENGINEERING, vol. 14, no. 10, 2001, pages 815 - 823 |
WELLS; LOWMAN, CURR. OPIN. STRUCT. BIOL., vol. 2, 1992, pages 597 |
ZOLA: "Monoclonal Antibodies: A Manual of Techniques", 1987, CRC PRESS INC., pages: 147 - 158 |
Cited By (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8030461B2 (en) | 2002-04-15 | 2011-10-04 | Chugai Seiyaku Kabushiki Kaisha | Methods for constructing scDb libraries |
US8337841B2 (en) | 2003-01-21 | 2012-12-25 | Chugai Seiyaku Kabushiki Kaisha | Methods of screening for antibody light chains |
US8597911B2 (en) | 2003-06-11 | 2013-12-03 | Chugai Seiyaku Kabushiki Kaisha | Process for producing antibodies |
US8062635B2 (en) | 2003-10-10 | 2011-11-22 | Chugai Seiyaku Kabushiki Kaisha | Bispecific antibody substituting for functional proteins |
US9493569B2 (en) | 2005-03-31 | 2016-11-15 | Chugai Seiyaku Kabushiki Kaisha | Structural isomers of sc(Fv)2 |
US10011858B2 (en) | 2005-03-31 | 2018-07-03 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
US11168344B2 (en) | 2005-03-31 | 2021-11-09 | Chugai Seiyaku Kabushiki Kaisha | Methods for producing polypeptides by regulating polypeptide association |
US8945543B2 (en) | 2005-06-10 | 2015-02-03 | Chugai Seiyaku Kabushiki Kaisha | Stabilizer for protein preparation comprising meglumine and use thereof |
US9241994B2 (en) | 2005-06-10 | 2016-01-26 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical compositions containing sc(Fv)2 |
US9777066B2 (en) | 2005-06-10 | 2017-10-03 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical compositions containing sc(Fv)2 |
US10934344B2 (en) | 2006-03-31 | 2021-03-02 | Chugai Seiyaku Kabushiki Kaisha | Methods of modifying antibodies for purification of bispecific antibodies |
US9670269B2 (en) | 2006-03-31 | 2017-06-06 | Chugai Seiyaku Kabushiki Kaisha | Methods of modifying antibodies for purification of bispecific antibodies |
US11046784B2 (en) | 2006-03-31 | 2021-06-29 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
US9828429B2 (en) | 2007-09-26 | 2017-11-28 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in CDR |
US11248053B2 (en) | 2007-09-26 | 2022-02-15 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in CDR |
US9334331B2 (en) | 2010-11-17 | 2016-05-10 | Chugai Seiyaku Kabushiki Kaisha | Bispecific antibodies |
US10450381B2 (en) | 2010-11-17 | 2019-10-22 | Chugai Seiyaku Kabushiki Kaisha | Methods of treatment that include the administration of bispecific antibodies |
US11124576B2 (en) | 2013-09-27 | 2021-09-21 | Chungai Seiyaku Kabushiki Kaisha | Method for producing polypeptide heteromultimer |
US11001643B2 (en) | 2014-09-26 | 2021-05-11 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing therapeutic agent |
US11150254B2 (en) | 2014-09-26 | 2021-10-19 | Chugai Seiyaku Kabushiki Kaisha | Method for measuring reactivity of FVIII |
US11214623B2 (en) | 2014-09-26 | 2022-01-04 | Chugai Seiyaku Kabushiki Kaisha | Antibody capable of neutralizing substance having activity alternative to function of coagulation factor VIII (FVIII) |
US9975966B2 (en) | 2014-09-26 | 2018-05-22 | Chugai Seiyaku Kabushiki Kaisha | Cytotoxicity-inducing theraputic agent |
US11142587B2 (en) | 2015-04-01 | 2021-10-12 | Chugai Seiyaku Kabushiki Kaisha | Method for producing polypeptide hetero-oligomer |
US11649262B2 (en) | 2015-12-28 | 2023-05-16 | Chugai Seiyaku Kabushiki Kaisha | Method for promoting efficiency of purification of Fc region-containing polypeptide |
US11352438B2 (en) | 2016-09-06 | 2022-06-07 | Chugai Seiyaku Kabushiki Kaisha | Methods of using a bispecific antibody that recognizes coagulation factor IX and/or activated coagulation factor IX and coagulation factor X and/or activated coagulation factor X |
US10759870B2 (en) | 2017-09-29 | 2020-09-01 | Chugai Seiyaku Kabushiki Kaisha | Multispecific antigen-binding molecules having blood coagulation factor VIII (FVIII) cofactor function-substituting activity and pharmaceutical formulations containing such a molecule as an active ingredient |
Also Published As
Publication number | Publication date |
---|---|
EP1500665B1 (en) | 2011-06-15 |
AU2003227504A1 (en) | 2003-10-27 |
US8030461B2 (en) | 2011-10-04 |
US20070087381A1 (en) | 2007-04-19 |
EP1500665A4 (en) | 2006-05-24 |
EP1500665A1 (en) | 2005-01-26 |
JPWO2003087163A1 (ja) | 2005-08-18 |
ATE512989T1 (de) | 2011-07-15 |
JP4386741B2 (ja) | 2009-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003087163A1 (fr) | Procede d'elaboration d'une banque scdb | |
US10501737B2 (en) | Method for producing antigen-binding molecule using modified helper phage | |
CA2544562C (en) | Bispecific antibodies | |
JP4794301B2 (ja) | 抗体の製造方法 | |
US20120184716A1 (en) | Methods for the Generation of Multispecific and Multivalent Antibodies | |
CA2978381A1 (en) | Chimeric antigen receptor (car) comprising a cd19-binding domain | |
JP2018537415A (ja) | 多価Fv抗体 | |
BR112021005472A2 (pt) | molécula de ligação ao antígeno compreendendo uma região variável do anticorpo alterada | |
US20050207977A1 (en) | Multimeric protein engineering | |
CA2177988A1 (en) | Expression vector for preparing an anti-body-variable-region library | |
EP1032660A1 (en) | Method of identifying binding site domains that retain the capacity of binding to an epitop | |
WO2007108152A1 (ja) | 高機能性二重特異性抗体 | |
KR20190139909A (ko) | 항-pd-l1/항-pd-1 천연 항체 구조-유사 헤테로다이머 이중특이성 항체 및 그의 제조 | |
JPH05500310A (ja) | 融合蛋白質の製造方法 | |
CN113195530A (zh) | 抗体融合蛋白、制备方法及其应用 | |
Leong et al. | Preparing recombinant single chain antibodies | |
CN114340668A (zh) | 结合于cd38和cd3的异源二聚抗体 | |
US20220354962A1 (en) | Rapid production of bispecific antibodies from off-the-shelf iggs with high yield and purity | |
US20090104660A1 (en) | Expression vector for secreting antibody fragment using e. coli signal sequence and method for mass-producing antibody fragment | |
CN104558181A (zh) | 靶向b淋巴瘤细胞的人源单链抗体 | |
CN113993886A (zh) | 可活化多特异性抗原结合蛋白复合物 | |
WO2024027120A1 (en) | Multi-specific polypeptide complexes | |
Weichel et al. | TandAbs: potent and well-manufacturable bi-specific antibodies | |
Bakshi | Engineering single domain antibodies into antivirals and vaccine delivery vehicles to combat infectious diseases | |
Remy et al. | Design and selection of anti-PD-L1 single-domain antibody and tumor necrosis factor superfamily ligands for an optimal vectorization in an oncolytic virus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003584118 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003717592 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003717592 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007087381 Country of ref document: US Ref document number: 10510971 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10510971 Country of ref document: US |